Stevanato Group (NYSE:STVN – Get Free Report) and Journey Medical (NASDAQ:DERM – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.
Risk and Volatility
Stevanato Group has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.
Valuation & Earnings
This table compares Stevanato Group and Journey Medical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Stevanato Group | $1.34 billion | 4.01 | $158.21 million | €0.59 | 30.15 |
| Journey Medical | $61.86 million | 2.95 | -$11.43 million | ($0.37) | -17.89 |
Stevanato Group has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
7.3% of Journey Medical shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by insiders. Comparatively, 14.5% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Stevanato Group and Journey Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Stevanato Group | 11.76% | 10.27% | 6.08% |
| Journey Medical | -14.82% | -35.57% | -10.88% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Stevanato Group and Journey Medical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Stevanato Group | 0 | 2 | 3 | 2 | 3.00 |
| Journey Medical | 1 | 1 | 2 | 0 | 2.25 |
Journey Medical has a consensus target price of $13.00, suggesting a potential upside of 96.37%. Given Journey Medical’s higher possible upside, analysts clearly believe Journey Medical is more favorable than Stevanato Group.
Summary
Stevanato Group beats Journey Medical on 11 of the 15 factors compared between the two stocks.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
About Journey Medical
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.
